FDA Signals Hemp CBD Enforcement Shift, But Industry Wants Legislation

The Food and Drug Administration has issued new enforcement guidance on hemp-derived CBD products, a move industry advocates are calling a step forward—but one that falls short of the comprehensive regulations needed to stabilize the $2 billion market.

"These products have the potential to reshape how Americans approach wellness by offering accessible, plant-based alternatives that complement traditional care, but realizing that potential will require more than enforcement discretion," said Thomas Winstanley of Edibles.com, a cannabis industry marketplace.

The FDA's updated approach comes after years of the hemp CBD sector operating in what Winstanley describes as a "paradox"—products that are federally legal under the 2018 Farm Bill, widely available in retail stores nationwide, and increasingly normalized by consumers, yet lacking clear regulatory pathways for manufacturing, labeling, and safety standards.

The Enforcement Gap

Since Congress legalized hemp and its derivatives in 2018, the FDA has maintained that CBD cannot be legally added to food or marketed as dietary supplements without agency approval. Yet enforcement has been inconsistent, with thousands of CBD products remaining on shelves at major retailers while the agency issued occasional warning letters to specific companies.

The new guidance attempts to clarify the FDA's enforcement priorities, though industry observers note it stops short of creating the formal regulatory framework that would allow companies to operate with certainty. The agency has not announced specific thresholds for THC content, standardized testing requirements, or clear labeling guidelines that manufacturers have requested for years.

"We're still operating in a gray area," said one CBD manufacturer who requested anonymity. "The enforcement discretion is welcome, but it doesn't solve the fundamental problem: we need actual rules."

The Congressional Path Forward

Industry groups have increasingly focused their efforts on Capitol Hill rather than waiting for FDA rulemaking. Several bills introduced in recent sessions would create explicit pathways for CBD in food and supplements, though none have advanced to floor votes.

The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act, reintroduced in the current Congress, would direct the FDA to issue regulations within two years. Sponsors argue the legislation would protect consumers through standardized testing and labeling while giving legitimate businesses clear compliance pathways.

But the bill faces the same challenge that has stalled previous hemp legislation: disagreement over how to handle intoxicating hemp derivatives like delta-8 THC, which have proliferated in the absence of clear rules. Some lawmakers want comprehensive reform that addresses all hemp cannabinoids, while others prefer narrower legislation focused solely on non-intoxicating CBD.

Market Implications

The regulatory uncertainty has created a two-tier market. Large corporations with legal teams and compliance budgets can navigate the ambiguity, while smaller producers struggle with state-by-state variations and the constant risk of enforcement action.

Market research firm Brightfield Group estimates the U.S. CBD market at $2.1 billion in 2024, down from a peak of $2.8 billion in 2021—a decline analysts attribute partly to regulatory confusion dampening investor confidence and limiting retail expansion.

"The FDA guidance might prevent further market contraction, but real growth requires legislative clarity," noted Bethany Gomez, managing director at Brightfield Group. "Investors want to see a defined regulatory pathway before committing significant capital."

What's Next

The FDA has not indicated whether the new enforcement approach represents a permanent policy shift or temporary guidance pending congressional action. The agency continues to maintain that it lacks sufficient safety data on CBD in food products, particularly for vulnerable populations like children and pregnant women.

Industry advocates say they're prepared to work with lawmakers on comprehensive legislation that addresses safety concerns while creating workable regulations. Whether Congress acts this session remains uncertain, but stakeholders agree the current regulatory limbo cannot continue indefinitely.

"We're at a crossroads," Winstanley said. "Either Congress steps in with real regulations, or we'll continue this patchwork approach that serves neither consumers nor businesses well."

---

This article is based on original reporting by www.marijuanamoment.net.